A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Study To Evaluate the Efficacy, Safety and Tolerability of E2027 in Subjects With Dementia With Lewy Bodies. DELPHIA
Study of E2027 in Subjects with Lewy Body Dementia (LBD) (DELPHIA)
Sponsor: EISAI
Enrolling: Male and Female Patients
IRB Number: AAAR9235
U.S. Govt. ID: NCT03467152
Contact: Evelyn Dominguez: 212-305-2371 / edd5@cumc.columbia.edu
Additional Study Information: This is a 22-week treatment, multicenter, double-blind, placebo-controlled, parallel group, Phase 2 study to evaluate the efficacy, safety, and tolerability of the study drug E2027, in participants with Dementia with Lewy Bodies (DLB) Lewy Body Dementia - LBD. The main purpose of this research study is to find if a new drug called E2027 works in people who have DLB. People with DLB have impairment in their cognitive function (things like language, concentration, thinking, reasoning and memory). They may also have other symptoms affecting their movement and mental status. E2027 is an investigational study drug that is thought to cause an increase in levels of a brain chemical known as cyclic guanosine monophosphate (cGMP). cGMP is a substance involved in how cells communicate within the brain. Increasing cGMP levels in the brain may improve cognitive function. The purpose of this study is to assess the safety (symptoms and medical problems you may experience - known as side effects), and efficacy (how well the study drug treats DLB) of the study drug. If you decide to participate, you will take the study drug orally (by mouth) once a day.
This study is closed
Lawrence Honig, MD, PhD
Do You Qualify?
Are you between the ages of 50-85 (inclusive)? Yes No
Do you have Dementia with Lewy Bodies (DLB)? Yes No
Do you have a caregiver or informant who is willing to provide follow-up information? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Evelyn Dominguez